Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 3/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14396684 | 0.90 | ALOX5AP (0.41) | ALOX5APACACBLMNAPOLBRAB9A | |
| SCHEMBL3002980 | 0.89 | APP (0.45) | ALOX5APAPPACACBLMNAPOLB | |
| SCHEMBL9924099 | 0.86 | ACACB (0.41) | ALOX5APACACBLMNAPOLBRAB9A | |
| SCHEMBL2798446 | 0.83 | ACACB (0.42) | ALOX5APACACBLMNAPOLBRAB9A | |
| SCHEMBL708933 | 0.82 | ALOX5AP (0.48) | ALOX5APAPPLMNAPOLBRAB9A | |
| SCHEMBL707622 | 0.81 | ALOX5AP (0.63) | ALOX5APACACBMMP9MMP13ADAM17 | |
| SCHEMBL709308 | 0.81 | ALOX5AP (0.63) | ALOX5APACACBMMP9MMP13ADAM17 | |
| SCHEMBL9924120 | 0.80 | ALOX5AP (0.46) | ALOX5APACACBMMP9MMP13ADAM17 | |
| SCHEMBL9924138 | 0.79 | ALOX5AP (0.38) | ALOX5APACACB | |
| SCHEMBL708956 | 0.79 | ALOX5AP (0.62) | ALOX5APAPPRAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2013174-B1 | DIARYL SUBSTITUTED ALKANES | MERCK SHARP & DOHME (US) | 2013-05-08 | — | — | EP | disclosed |
| US-8426413-B2 | Diaryl substituted alkanes | MERCK SHARP & DOHME CORP. (US) | 2013-04-23 | — | — | US | disclosed |
| US-8426413-B2 | Diaryl substituted alkanes | MERCK SHARP & DOHME CORP. (US) | 2013-04-23 | — | — | US | disclosed |
| US-20120149674-A1 | Diaryl Substituted Alkanes | MERCK SHARPE & DOHME CORP. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149674-A1 | Diaryl Substituted Alkanes | MERCK SHARPE & DOHME CORP. (US) | 2012-06-14 | — | — | US | disclosed |
| US-8124628-B2 | Diaryl substituted alkanes | MERCK SHARP & DOHME CORP. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124628-B2 | Diaryl substituted alkanes | MERCK SHARP & DOHME CORP. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20090258851-A1 | DIARYL SUBSTITUTED ALKANES | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
| US-20090258851-A1 | DIARYL SUBSTITUTED ALKANES | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149674-A1 | Diaryl Substituted Alkanes | ALOX5, ALOX15, LTB4R2 | ALOX5AP 13/4885APP 621/4885ACACB 578/4885 |
| US-20090258851-A1 | DIARYL SUBSTITUTED ALKANES | ALOX5, ALOX15, LTB4R2 | ALOX5AP 13/4885APP 621/4885ACACB 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.